The content of this publication does not necessarily reflect the

The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names,

commercial products, or organization imply endorsement by the U.S. Government. References 1. Gomez-Raposo C, Mendiola M, Barriuso J, Casado E, Hardisson D, Redondo A: Angiogenesis and ovarian cancer. Clin Transl Oncol 2009, 11:564–571.PubMedCrossRef 2. Griffioen AW, Molema G: Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol Rev 2000, 52:237–268.PubMed 3. Rini BI: Vascular endothelial growth factor-targeted therapy in metastatic renal cell carcinoma. Cancer 2009, 115:2306–2312.PubMedCrossRef 4. Gressett SM, Shah SR: Intricacies of bevacizumab-induced Ilomastat mw toxicities and their management. Ann Pharmacother 2009, 43:490–501.PubMedCrossRef

5. Porta C, Paglino C, Imarisio I, Bonomi L: Uncovering Pandora’s vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib. Clin Exp Med 2007, 7:127–134.PubMedCrossRef 6. Launay-Vacher V, Deray G: Hypertension and proteinuria: a class-effect of antiangiogenic Selleck Belnacasan therapies. Anticancer Drugs 2009, 20:81–82.PubMedCrossRef 7. Azad NS, Aragon-Ching JB, Dahut WL, Gutierrez M, Figg WD, Jain L, Steinberg SM, Turner ML, Kohn EC, Kong HH: Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy. Clin Cancer Res 2009, 15:1411–1416.PubMedCrossRef 8. Fuh G, Li B, Crowley C, Cunningham B, Wells JA: selleck chemical Requirements for

binding and signaling of the kinase domain receptor for vascular endothelial growth factor. J Biol Chem 1998, 273:11197–11204.PubMedCrossRef 9. Tao Q, Backer MV, Backer JM, Terman BI: Kinase insert domain receptor (KDR) extracellular immunoglobulin-like domains 4–7 contain structural features that block receptor dimerization and vascular endothelial growth factor-induced signaling. J Biol Chem 2001, 276:21916–21923.PubMedCrossRef 10. Wang Y, Zheng Y, Zhang W, Yu H, Lou K, Zhang Y, Qin Q, Zhao B, Yang Y, Hui R: Polymorphisms of KDR gene are associated with coronary heart disease. J Am Coll Cardiol 2007, 50:760–767.PubMedCrossRef 11. Aragon-Ching JB, Jain L, Gulley JL, Arlen PM, Wright JJ, Steinberg SM, Draper D, Venitz J, Jones E, Chen CC, et al.: Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer. BJU Int 2009, 103:1636–1640.PubMedCrossRef 12. YM Ning JG, Arlen P, Latham L, Retter A, Wright J, Parnes H, Pinto P, Figg WD, Dahut WL: Phase II trial of thalidomide, bevacizumab, and docetaxel in patients (pts) with metastatic androgen-independent prostate cancer (AIPC). American Society of Clinical Oncology (ASCO) 2007. 13.

Comments are closed.